Eltrombopag: A novel oral thrombopoietin receptor agonist

Annals of Pharmacotherapy

Volumn 44, Issue 6, 2010, Pages 1072-1079

  Corman, Shelby L ^a,b   Mohammad, Rima A ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Eltrombopag; Hepatitis C virus; Idiopathic thrombocytopenic purpura; Immune thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; ELTROMBOPAG; IMMUNOGLOBULIN; PLACEBO; ROMIPLOSTIM; SB 497115GR; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CATARACT; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECCHYMOSIS; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER CIRRHOSIS; LIVER TOXICITY; MENORRHAGIA; MYALGIA; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; BENZOIC ACIDS; HUMANS; HYDRAZINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA;

EID: 77952904546     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P042     Document Type: Review

References (23)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
2. Seagal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2008;4:2377-2383
3. Fuedjo-Tepie MA, Robinson D, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6:711-712 (Pubitemid 351404943)
4. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
5. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009;60:93-206.
6. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236 (Pubitemid 350190753)
7. GlaxoSmithKline. Eltrombopag treatment of thrombocytopenia in subjects with advanced myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia after MDS (sAML/MDS). Clinicaltrials.gov Identifier: NCT00903422. http://clinicaltrials.gov/ct2/show/NCT00903422. (accessed 2010 Mar 17).
8. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-4741 (Pubitemid 46827766)
9. Product Information. PROMACTA (eltrombopag). Research Triangle Park, NC: GlaxoSmithKline, October 2008. www.promactacares.com/prescribing-information.pdf (accessed 2009 Dec 20).
10. Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009;37:1030-1037
11. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357: 2237-2247 (Pubitemid 350190754)
12. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-648
13. Bussel J, Psaila B, Saleh M, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura (abstract 3431). Blood 2008;112:1176.
14. Cheng C, Saleh M, Bussel J, et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE) (abstract 400). Blood 2008;112:400. Presented at: 50th annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2008.
15. Bussel J, Cheng G, Saleh M, et al. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura (abstract 3432). Blood 2008;112:1177. Presented at: 50th annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2008.
16. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48:1000-1007
17. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114:3899-3908
18. Jenkins J, Williams D, Deng Y, et al. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 2010; 66:67-76.
19. Williams DD, Peng B, Bailey C, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 2009;31:764-776
20. PROMACTA CARES Overview for Healthcare Providers. www. promactacares.com (accessed 2009 Jan 22).
21. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
22. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children, and pregnancy. Br J Haematol 2003;120:574-596
23. Cohen HE, ed. Drug topics red book. Montvale, NJ: Thomson PDR, 2009.